骨松益骨方联合阿仑膦酸钠治疗脾肾气虚血瘀型原发性骨质疏松症的疗效观察
|
摘要
目的:观察骨松益骨方联用阿仑膦酸钠治疗脾肾气虚血瘀型原发性骨质疏松症的疗效。方法:将186例脾肾气虚血瘀型原发性骨质疏松症患者随机分为3组,包括骨松益骨方组63例、阿仑膦酸钠组61例和联用组62例,治疗6个月后,观察3组治疗前后的骨密度、疼痛症状评分、骨代谢指标及脆性骨折发生率的改善情况。结果:治疗前后比较,3组均能有效防止骨密度下降;骨痛症状有不同程度的改善;骨吸收得到显著抑制;脆性骨折发生率也明显降低(P<0.05)。联用组与单用组相比,联用组的各项指标均优于骨松益骨方组和阿仑膦酸钠组(P<0.05)。结论:骨松益骨方和阿仑膦酸钠均可改善脾肾气虚血瘀型原发性骨质疏松症患者的疼痛症状,提高骨密度,降低骨转换,联用效果更佳。
Objective: To observe the effects of Gusong Yigu decoction(骨松益骨方,GSYGD) combined with alendronate sodium tablets on the primary osteoporosis patients who possessed qi deficiency of kidney-spleen and blood stasis. Methods: The186 patients with primary osteoporosis were collected and divided into three groups, 63 patients in GSYGD group, 61 patients in alendronate sodium tablets group and 62 patients in combination group. Bone mineral density, pain score, blood calcium, blood phosphorus, bone metabolism markers and incidence rate of bone fragile fracture were investigated after the treatment of 6months. Results: Compared with pre-therapy, GSYGD and alendronate sodium tablets could prevent the decrease of bone mineral density, relieve the skeletal pain, inhibit bone resorption and decrease the incidence rate of bone fragile fracture( P <0.05), no matter combination or alone. However, all these markers in the combination group are better than the GSYGD and alendronate sodium tablets group(P<0.05). Conclusion: Gusong Yigu decoction and alendronate sodium tablets both could improve the clinial symptoms in primary osteoporosis patients with qi deficiency of kidney-spleen and blood stasis, but combination could get better results.
Objective: To observe the effects of Gusong Yigu decoction(骨松益骨方,GSYGD) combined with alendronate sodium tablets on the primary osteoporosis patients who possessed qi deficiency of kidney-spleen and blood stasis. Methods: The186 patients with primary osteoporosis were collected and divided into three groups, 63 patients in GSYGD group, 61 patients in alendronate sodium tablets group and 62 patients in combination group. Bone mineral density, pain score, blood calcium, blood phosphorus, bone metabolism markers and incidence rate of bone fragile fracture were investigated after the treatment of 6months. Results: Compared with pre-therapy, GSYGD and alendronate sodium tablets could prevent the decrease of bone mineral density, relieve the skeletal pain, inhibit bone resorption and decrease the incidence rate of bone fragile fracture( P <0.05), no matter combination or alone. However, all these markers in the combination group are better than the GSYGD and alendronate sodium tablets group(P<0.05). Conclusion: Gusong Yigu decoction and alendronate sodium tablets both could improve the clinial symptoms in primary osteoporosis patients with qi deficiency of kidney-spleen and blood stasis, but combination could get better results.
引文
[1]刘忠厚.骨矿与临床[M].北京:中国科学技术出版社,2006:2-634.
[2]Dobnig H,Stepan JJ,Burr DB,et al.Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate[J].Journal of Bone and Mineral Research,2009,24(12):1998-2005.
[3]刘梅洁,潘静华,李艳,等.左归丸对糖皮质激素所致骨质疏松大鼠血清中BGP,IGF-I含量的影响[J].中国实验方剂学杂志,2011,17(16):133-136.
[4]甘国兴,莫新民,李劲平,等.壮骨止痛方无水乙醇提取A部位对去势雌鼠骨质疏松的疗效及机制研究[J].中国实验方剂学杂志,2011,17(17):147-150.
[5]中国老年学学会骨质疏松委员会骨质疏松诊断标准学科组.中国人骨质疏松症建议诊断标准(第2稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[6]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:357-358.
[7]王悦.目测类比评定法在颈肩腰痛患者中的应用[J].中华物理医学与康复杂志,2002,24(10):602.
[8]任建宏.金乌骨通合阿仑膦酸钠对绝经后骨质疏松症患者疼痛的影响[J].中医药导报,2011,17(1):60-61.
[9]孔西建,吴丹,叶进,等.益肾活血法对原发性骨质疏松症患者骨密度、骨代谢及脆性骨折发生率的影响[J].中医杂志,2014,55(5):391-395.
[10]Zhai YK,Guo X,Pan YL,et al.A systematic review of the efficacy and pharmacological profile of Herba Epimedii in osteoporosis therapy[J].Pharmazie,2013,68(9):713-722.
[11]Peng S,Zhang G,He Y,et al.Epimedium-derived flavonoids promote osteoblastogenesis and suppress adi-pogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone[J].Bone,2009,45(3):534-544.
[12]Kong XH,Niu YB,Song XM,et al.Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8pathways[J].International Journal of Molecular Medicine,2012(29):1090-1098.
[13]Zhang R,Liu ZG,Lia C,et al.Du-Zhong(Eucommia ulmoides Oliv.)cortex extract prevent OVX-induced osteoporosis in rats[J].Bone,2009,45(3):553-559.
[2]Dobnig H,Stepan JJ,Burr DB,et al.Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate[J].Journal of Bone and Mineral Research,2009,24(12):1998-2005.
[3]刘梅洁,潘静华,李艳,等.左归丸对糖皮质激素所致骨质疏松大鼠血清中BGP,IGF-I含量的影响[J].中国实验方剂学杂志,2011,17(16):133-136.
[4]甘国兴,莫新民,李劲平,等.壮骨止痛方无水乙醇提取A部位对去势雌鼠骨质疏松的疗效及机制研究[J].中国实验方剂学杂志,2011,17(17):147-150.
[5]中国老年学学会骨质疏松委员会骨质疏松诊断标准学科组.中国人骨质疏松症建议诊断标准(第2稿)[J].中国骨质疏松杂志,2000,6(1):1-3.
[6]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:357-358.
[7]王悦.目测类比评定法在颈肩腰痛患者中的应用[J].中华物理医学与康复杂志,2002,24(10):602.
[8]任建宏.金乌骨通合阿仑膦酸钠对绝经后骨质疏松症患者疼痛的影响[J].中医药导报,2011,17(1):60-61.
[9]孔西建,吴丹,叶进,等.益肾活血法对原发性骨质疏松症患者骨密度、骨代谢及脆性骨折发生率的影响[J].中医杂志,2014,55(5):391-395.
[10]Zhai YK,Guo X,Pan YL,et al.A systematic review of the efficacy and pharmacological profile of Herba Epimedii in osteoporosis therapy[J].Pharmazie,2013,68(9):713-722.
[11]Peng S,Zhang G,He Y,et al.Epimedium-derived flavonoids promote osteoblastogenesis and suppress adi-pogenesis in bone marrow stromal cells while exerting an anabolic effect on osteoporotic bone[J].Bone,2009,45(3):534-544.
[12]Kong XH,Niu YB,Song XM,et al.Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8pathways[J].International Journal of Molecular Medicine,2012(29):1090-1098.
[13]Zhang R,Liu ZG,Lia C,et al.Du-Zhong(Eucommia ulmoides Oliv.)cortex extract prevent OVX-induced osteoporosis in rats[J].Bone,2009,45(3):553-559.